Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

21. Type 2 diabetes can be reversed with a low-calorie diet

Type 2 diabetes can be reversed with a low-calorie diet Signal - Type 2 diabetes can be reversed with a low-calorie diet Dissemination Centre Discover Portal NIHR DC Discover Type 2 diabetes can be reversed with a low-calorie diet Published on 13 February 2018 Nearly half of people given a formula replacement diet of 830 calories per day for three to five months, followed by food reintroduction, went into remission from type 2 diabetes. They were supported to achieve and maintain weight (...) reduction by primary care nurses or dieticians. This trial involved 298 adults who had been diagnosed with type 2 diabetes within six years. Those that stuck with the program were more likely to lose weight (average 10kg was lost) and to go into remission compared to usual care. More than two-thirds of them were also able to stop both diabetic and high blood pressure tablets. These results were seen after one year. The challenge will be to see if the results can be maintained over the planned four year

NIHR Dissemination Centre2018

22. Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes

Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Signal - Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Dissemination Centre Discover Portal NIHR DC Discover Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Published on 11 July 2017 People with type 1 diabetes offered insulin pumps did not achieve better blood glucose control compared with those using (...) observed benefits from pump treatment might actually have been a reflection of the training given to them. Currently just 10% of adults with type 1 diabetes access these training courses. These results support NICE guidelines around the restricted use of insulin pumps and suggest that training improves self-management of the condition. Efforts should therefore be made to encourage training uptake. Share your views on the research. Why was this study needed? People with type 1 diabetes require lifelong

NIHR Dissemination Centre2018

23. Continuous insulin pumps may help manage poorly controlled type 2 diabetes

. Other studies have found that this may be improved with continuous insulin pumps. Larger studies will be required to confirm if this is the case and to assess the safety of the technique for advanced type 2 diabetes as it is currently only recommended for type 1 diabetes. This treatment option is more expensive than multiple daily injections so cost-effectiveness will also need to be looked at. Nevertheless, these are promising results for people with poorly controlled type 2 diabetes. Share your (...) options for advanced stages of the disease, but approximately one in every four people on insulin injections has a very poor control of blood sugar levels. Evidence on insulin pumps in type 2 diabetes is sparse compared to the evidence in type 1 diabetes. This study aimed to assess blood sugar control using continuous subcutaneous insulin infusions in type 2 diabetes in order to inform the development of patient-centred treatment approaches. What did this study do? This meta-analysis included five

NIHR Dissemination Centre2018

24. Type 2 diabetes is becoming more common in children

Type 2 diabetes is becoming more common in children Signal - Type 2 diabetes is becoming more common in children Dissemination Centre Discover Portal NIHR DC Discover Type 2 diabetes is becoming more common in children Published on 25 July 2017 The number of children being diagnosed with both type 1 and type 2 diabetes is rising, but new cases of type 2 diabetes, the form associated with being overweight, has risen five-fold in about five years. New analysis in this NIHR-supported study suggest (...) diabetes type 1 and 2 has been rising for several years. Obesity is a well-known risk factor for type 2 diabetes in adults. But there has been little large-scale research about the link between childhood obesity and diabetes. Over a third of children and young adults were overweight or obese in the UK in 2015, with one in five children obese by the time they leave primary school. This study aimed to examine trends in the incidence of both types of diabetes, as well as any association between high BMI

NIHR Dissemination Centre2018

25. Flu vaccine reduces deaths for people with type 2 diabetes

Flu vaccine reduces deaths for people with type 2 diabetes Signal - Flu vaccine reduces deaths for people with type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover Flu vaccine reduces deaths for people with type 2 diabetes Published on 18 October 2016 Flu vaccination helps prevent some deaths, serious strokes, heart failure and pneumonia in people with type 2 diabetes. Vaccination is linked to less hospital admissions for these reasons, but there is no link to rates (...) of admissions for heart attack. The results come from a reliable population-based study that looked back at the general practice and hospital records of almost 125,000 adults with type 2 diabetes in England. Outcome rates were compared between those who had and hadn’t received the flu vaccine over seven successive flu seasons. The researchers carefully adjusted for things like the seasonal change in flu numbers. The findings strongly support current recommendations that people with chronic medical

NIHR Dissemination Centre2018

26. Sulfonylureas can be considered safe for those with type 2 diabetes

looking at the timing of use of sulfonylureas – as first-line treatment, second-line treatment, unspecified, or specifically as add-on therapy to metformin. Statistical analysis found that the overall sample size was large enough to conclude that the number of people harmed by sulfonylureas is likely to be less than 1 in 200. What does current guidance say on this issue? NICE’s 2015 guidance on type 2 diabetes recommends a sulfonylurea as an initial treatment option if the standard first-choice drug (...) Sulfonylureas can be considered safe for those with type 2 diabetes Signal - Sulfonylureas can be considered safe for those with type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover Sulfonylureas can be considered safe for those with type 2 diabetes Published on 20 July 2016 This large review finds that sulfonylurea drugs are not associated with an increased risk of death, heart attack or stroke when compared with placebo, diet control or other diabetes drugs. Sulfonylureas

NIHR Dissemination Centre2018

27. Motivational interviewing may encourage healthy eating in people with type 2 diabetes

Motivational interviewing may encourage healthy eating in people with type 2 diabetes Signal - Motivational interviewing may encourage healthy eating in people with type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover Motivational interviewing may encourage healthy eating in people with type 2 diabetes Published on 15 March 2016 A motivational communication approach may help people with type 2 diabetes eat more healthily, but may be no better than usual care for changing other (...) type 2 diabetes that, if not managed well, can cause serious long-term health problems including heart disease, stroke, blindness and amputations leading to disability. Good management includes education for a healthy diet, exercise and maintaining blood glucose levels within safe limits. Motivational interviewing is a counselling approach used to motivate people to change their behaviour, so could be useful in encouraging good diabetes self-management. It typically involves open-ended questions, reflective

NIHR Dissemination Centre2018

28. Self-monitoring of blood glucose provides no important benefit for most people with type 2 diabetes

in blood sugar control. This is not enough to be clinically important or outweigh the costs and personal inconvenience of long-term self-testing. Self-monitoring is a well-established strategy for type 1 diabetes and for people with type 2 who need insulin. The benefit for all people with type 2 is debatable. This review pooled 24 randomised controlled trials comparing self-monitoring with any control strategy for people not taking insulin. Self-monitoring gave a 0.3 percentage point reduction (...) , Riphagen II, et al. . Cochrane Database of Syst Rev. 2012;(1):CD005060. Why was this study needed? There are around 3.7 million people living with diabetes in the UK. Around 90% of those affected have type 2 diabetes. Management of type 2 diabetes usually begins with lifestyle changes, followed by the addition of oral blood-glucose-lowering medications, progressing to additional drugs and insulin if needed. Blood glucose is monitored by measuring HbA1c every three to six months. The aim is to keep

NIHR Dissemination Centre2018

29. T cell activation and cardiovascular risk in type 2 diabetes mellitus: a protocol for a systematic review and meta-analysis.

T cell activation and cardiovascular risk in type 2 diabetes mellitus: a protocol for a systematic review and meta-analysis. INTRODUCTION: The burden of non-communicable diseases such as type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) has drastically increased in developing countries over the years. Although recent evidence points to chronic immune activation to be a significant aspect in the pathogenesis and development of T2DM and CVDs, the exact role of T cells

Systematic Reviews2018

30. Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity.

Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity. Importance: Macrovascular disease is a leading cause of morbidity and mortality for patients with type 2 diabetes, and medical management, including lifestyle changes, may not be successful at lowering risk. Objective: To investigate the relationship between bariatric surgery and incident macrovascular (coronary artery disease and cerebrovascular diseases) events (...) in patients with severe obesity and type 2 diabetes. Design, Setting, and Participants: In this retrospective, matched cohort study, patients with severe obesity (body mass index ≥35) aged 19 to 79 years with diabetes who underwent bariatric surgery from 2005 to 2011 in 4 integrated health systems in the United States (n = 5301) were matched to 14 934 control patients on site, age, sex, body mass index, hemoglobin A1c, insulin use, observed diabetes duration, and prior health care utilization, with follow

JAMA2018

31. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. BACKGROUND: LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. We aimed to examine the efficacy and safety of co-stimulation of the GLP-1 and GIP receptors (...) with LY3298176 compared with placebo or selective stimulation of GLP-1 receptors with dulaglutide in patients with poorly controlled type 2 diabetes. METHODS: In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks. Assignment was stratified by baseline glycated haemoglobin A 1c (HbA 1c ), metformin use

Lancet2018

32. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. BACKGROUND: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. We aimed to evaluate the long-term effects of lorcaserin on diabetes prevention (...) , and 1193 (9·9%) normoglycaemia. At 1 year, patients treated with lorcaserin had a net weight loss beyond placebo of 2·6 kg (95% CI 2·3-2·9) for those with diabetes, 2·8 kg (2·5-3·2) for those with prediabetes, and 3·3 kg (2·6-4·0) for those with normoglycaemia (p<0·0001 for all analyses). Lorcaserin reduced the risk of incident diabetes by 19% in patients with prediabetes (172 [8·5%] of 2015 vs 204 [10·3%] of 1976; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·038) and by 23% in patients without diabetes

Lancet2018

34. Sleeve Gastrectomy Compared to Gastric Bypass as a Treatment for Type 2 Diabetes in those with a BMI < 35

Sleeve Gastrectomy Compared to Gastric Bypass as a Treatment for Type 2 Diabetes in those with a BMI < 35 "Sleeve Gastrectomy Compared to Gastric Bypass as a Treatment for Type " by Caitlyn Suelter < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Thirty million people in the United States have diabetes, of which, nearly 90% are considered overweight or obese (...) . Bariatric surgery, with the two most popular types being sleeve gastrectomy (SG) and gastric bypass (GB), is currently indicated as a treatment of type 2 diabetes (T2D) in those with a BMI > 35. However, recent studies have shown bariatric surgery to be an effective treatment in those with BMI Methods: An exhaustive literature search was completed using the following search engines: CINAHL-EBSCOhost, Web of Science, and MEDLINE-PubMed, and the following search terms: bariatric surgery, type 2 diabetes, and BMI

Pacific University EBM Capstone Project2018

35. Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes

Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes 30039616 2018 08 24 1463-1326 2018 Jul 23 Diabetes, obesity & metabolism Diabetes Obes Metab Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. 10.1111/dom.13474 A slight increase in melanoma risk was observed among sodium-glucose co-transporter-2 (SGLT-2 (...) to the type of SGLT-2 inhibitor, type of control, ages of patients, race/ethnicity, and trial durations. For non-melanoma skin cancer risk, no significant difference was observed when all trials were combined (Peto OR, 0.70; 95% CI, 0.47-1.07; I 2 , 0%), while a significantly decreased risk was observed among trials with duration <52 weeks (Peto OR, 0.12; 95% CI, 0.02-0.59; I 2 , 0%). No evidence of publication bias was detected in the analyses. Current evidence from RCTs did not support a significantly

EvidenceUpdates2018

36. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy

. Thus, this population-based study aimed to determine whether use of GLP-1 RAs is associated with an increased risk of incident diabetic retinopathy. Using the U.K. Clinical Practice Research Datalink, we conducted a cohort study among 77,115 patients with type 2 diabetes initiating antidiabetic drugs between January 2007 and September 2015. Adjusted hazard ratios (HRs) and 95% CIs of incident diabetic retinopathy were estimated using time-dependent Cox proportional hazards models, comparing use (...) associated with a decreased risk of diabetic retinopathy (HR 0.67, 95% CI 0.51-0.90). The associations with diabetic retinopathy varied according to the type of comparator. When compared with use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy. The apparent lower risk of diabetic retinopathy associated with GLP-1 RAs compared with insulin may be due to residual confounding. © 2018 by the American Diabetes Association

EvidenceUpdates2018

37. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis

Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis 30058208 2018 09 03 1463-1326 2018 Jul 29 Diabetes, obesity & metabolism Diabetes Obes Metab Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. 10.1111/dom.13484 We conducted a systematic review and meta-analysis of randomized controlled trials to assess the effect of glucagon-like peptide-1 (...) receptor agonists (GLP-1 RAs) on microvascular endpoints in adult patients with type 2 diabetes. We included 60 studies with 60 077 patients. GLP-1 RAs marginally reduced urinary albumin-to-creatinine ratio compared with placebo or other antidiabetic agents (weighted mean difference - 2.55 mg/g; 95% confidence interval [CI] -4.37 to -0.73 and -5.52; -10.89 to -0.16, respectively) and had no clinically relevant effect on change in estimated glomerular filtration rate. Treatment with GLP-1 RAs did

EvidenceUpdates2018

38. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study 30019498 2018 08 17 1463-1326 2018 Jul 18 Diabetes, obesity & metabolism Diabetes Obes Metab A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. 10.1111/dom.13473 (...) To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c ≥7.0 to ≤9.5% (≥53 to ≤80 mmol/mol) and estimated glomerular filtration rate ≥60 to <90 mL/min/1.73m 2 on metformin (≥1500 mg/d) ± sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks

EvidenceUpdates2018

39. Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment

glargine 300 U/mL (Gla-300) and insulin glargine 100 U/mL (Gla-100). A meta-analysis was performed using pooled 6-month data from the EDITION 1, 2 and 3 trials (N = 2496). Eligible participants, aged ≥18 years with a diagnosis of type 2 diabetes (T2DM), were randomized to receive once-daily evening injections of Gla-300 or Gla-100. Pooled results were assessed by two renal function subgroups: estimated glomerular filtration rate (eGFR) <60 and ≥60 mL/min/1.73 m 2 . The decrease in glycated haemoglobin (...) Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment 30003642 2018 08 30 1463-1326 2018 Jul 13 Diabetes, obesity & metabolism Diabetes Obes Metab Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. 10.1111/dom.13470 To investigate the impact of renal function on the safety and efficacy of insulin

EvidenceUpdates2018

40. Risk of hypoglycaemia in people aged >/=65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus

Risk of hypoglycaemia in people aged >/=65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus 30216648 2018 09 14 1742-1241 72 10 2018 Oct International journal of clinical practice Int. J. Clin. Pract. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. e13240 10.1111/ijcp.13240 To investigate the risk of hypoglycaemia in people aged ≥65 years with type 2 diabetes (...) mellitus (T2DM) treated with linagliptin, in the largest pooled analysis performed to date. One thousand four hundred and eighty-nine patients aged ≥65 years with T2DM were pooled from 11 randomised, double-blind, parallel group, placebo-controlled trials evaluating linagliptin 5 mg alone, or in addition to various background therapies. The primary safety endpoint was the incidence of investigator-defined hypoglycaemia. There was no significant difference in the risk of hypoglycaemia between

EvidenceUpdates2018